Drug intelligence / Profile preview

GWH001

Development stage: Preclinical
Lead developer: Ginwa Enterprise Group
Modality: Small Molecules
Administration: Inhalation

Overview

GWH001 is a small molecule drug candidate developed by GINWA Pharmaceutical Factory, currently in the preclinical stage of development. It is being investigated for the treatment of salivary gland damage resulting from radiotherapy in cancer patients. Radiotherapy-induced xerostomia (dry mouth) is a common and often permanent side effect of head and neck cancer treatment, significantly impacting patient quality of life by affecting speech, swallowing, and oral health. GWH001 is categorized as a Class 1 chemical drug under Chinese regulatory standards, indicating it is a new molecular entity.

Beyond the preview

Go deeper on GWH001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GWH001.

Explore the full profile